Premium
Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials
Author(s) -
Tarantino Michael D.,
Despotovic Jenny,
Roy John,
Grainger John,
Cooper Nichola,
Beam Donald,
Raj Ashok,
Maschan Alexey,
Kim June,
Eisen Melissa
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28630
Subject(s) - romiplostim , medicine , adverse effect , placebo , immune thrombocytopenia , thrombopoietin , clinical trial , interim analysis , thrombopoietin receptor , clinical endpoint , platelet , pediatrics , genetics , alternative medicine , stem cell , pathology , haematopoiesis , biology
Abstract Background Treatment for chronic immune thrombocytopenia (cITP) in children is largely limited to immunosuppressive agents. Thrombopoietin receptor agonists (TRAs) have been used to treat cITP in adults for over a decade. The objective of this integrated analysis was to examine the safety and efficacy of the TRA romiplostim in children with ITP. Methods We examined efficacy and safety in children with ITP across five romiplostim trials: final data from two double‐blind placebo‐controlled trials and two open‐label extensions, and interim data from an ongoing single‐arm trial. Results Patients (n = 24 initially placebo; n = 262 initially romiplostim) had a median age of 10.0 years (Q1: 6.0, Q3: 13.0), ITP duration of 1.9 years (Q1: 1.0, Q3: 4.0), and baseline platelet count of 14.3 × 10 9 /L (Q1: 7.5, Q3: 23.0). Among 282 patients receiving romiplostim, median treatment duration was 65 weeks (range 8‐471 weeks) and median weekly dose was 6.6 μg/kg (range 0.1‐9.7 μg/kg). Overall, 89% of romiplostim‐treated patients had platelet responses. Nineteen patients (7%) maintained treatment‐free responses for ≥6 months while withholding all ITP therapy. Grade 3 and 4 adverse events of bleeding occurred in 10% and <1% of romiplostim‐treated patients, respectively. Twenty‐five percent of patients had a serious adverse event, most commonly epistaxis (6%). Seven patients (2%) had neutralizing antibodies against romiplostim postbaseline and none had neutralizing antibodies against endogenous thrombopoietin. Efficacy and safety results appeared similar between children with ITP for ≤12 months and >12 months at baseline. Conclusions Across five pediatric clinical trials, romiplostim was well tolerated. Most patients had a platelet response; some maintained responses for at least 6 months while withholding all ITP therapy.